Active Biotech AB Interim report January – June 2016

      
Laquinimod

  • The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan
  • The study results from both the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) and the Phase 2 study ARPEGGIO, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected in the first half of 2017
  • Positive results concerning laquinimod were presented at the 68th AAN Annual Meeting (American Academy of Neurology), held in Vancouver, Canada, on April 15-21, 2016

Tasquinimod     

  • The complete study results of the Phase 3 10TASQ10 study have been published in the Journal of Clinical Oncology
  • Out-licensing activities are continuing

ANYARA, Paquinimod (57-57) and SILC (ISI)

  • Out-licensing activities are continuing

Financial summary

SEK M   Q2    Q1-Q2 Full Year
  2016 2015 2016 2015 2015
           
Net sales 3.9 3.2 7.9 6.1 16.3
Operating loss -14.5 -70.1 -30.6 -127.5 -177.9
Loss for the period -15.5 -71.4 -32.3 -129.3 -193.5
Loss per share, before and after dilution (SEK) -0.17 -0.79 -0.36 -1.44 -2.15
Cash and cash equivalents (at the end of the period)     57.4 186.6 103.6
  • Refocusing of the company is completed, operating costs reduced by 71% (SEK 95.2 M) compared with 2015
     
  • The number of employees will be reduced from 56 (June 2015) to 17 by the end of the third quarter of 2016
     
  • Operations are progressing according to plan pending the Phase 3 results for laquinimod in the first half of 2017

For further information, please contact:     

  Tomas Leanderson, President and CEO
  Tel: +46 46 19 20 95

 

  Hans Kolam, CFO
  Tel: +46 46 19 20 44

 
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 05

 

The report is also available at www.activebiotech.com.

HUG#2034058

Ads